drugset / Trial / NCT01160003

A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.

NCT01160003

Phase 1 Completed 12 enrolled GlaxoSmithKline
RandomizedCrossoverTriple-blindOther

Summary

This study is a randomised, double-blind, placebo-controlled, dose ascending, 3-way crossover study in healthy adult male volunteers. The primary objective of the study is to assess the pharmacokinetics of 14 days dosing of GW870086X administered via nebules formulation. The secondary objective is to assess the safety and tolerability of repeat doses of nebulised GW870086X.

Timeline

Start
2010-07-29
Primary completion
2010-11-05
Completion
2010-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GW870086 Small molecule 5 mg Inhaled
Subject GW870086 Small molecule 8.75 mg Inhaled

Indications